Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

Impel Pharmaceuticals logo

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.04
$0.84
52-Week Range
N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IMPL Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Impel Pharmaceuticals Inc. (IMPLQ)
See More Headlines

IMPL Stock Analysis - Frequently Asked Questions

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.42. The business had revenue of $0.09 million for the quarter.
Read the conference call transcript
.

Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Impel Pharmaceuticals investors own include Athenex (ATNX), NIO (NIO), KLX Energy Services (KLXE), American Airlines Group (AAL), Bolt Biotherapeutics (BOLT), Moderna (MRNA) and Novavax (NVAX).

Company Calendar

Last Earnings
11/15/2021
Today
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMPL
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,310,000.00
Net Margins
-353.93%
Pretax Margin
-353.93%

Debt

Sales & Book Value

Annual Sales
$20.99 million
Price / Cash Flow
N/A
Book Value
($1.86) per share
Price / Book
N/A

Miscellaneous

Free Float
22,418,000
Market Cap
$956,000.00
Optionable
Not Optionable
Beta
1.17
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IMPL) was last updated on 5/9/2025 by MarketBeat.com Staff
From Our Partners